Stockscreener 앱 받기
0.9807
2.90%
-0.0293
시간 외 거래:
.99
0.0093
+0.95%
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Investment Review: Does Entergy Texas Inc have a sustainable dividendJuly 2025 Snapshot & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Stock Report: Is Oncolytics Biotech Inc forming a breakout pattern - baoquankhu1.vn
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - Cantech Letter
Record $2.5B Sector Start Spotlights Clinical Oncology Plays - Baystreet.ca
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium - PR Newswire
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - Investing News Network
Late-Stage Breakthroughs: How 2026’s Top Clinical Platforms Are Redefining Cancer Treatment - Cantech Letter
Performance Recap: What is Oncolytics Biotech Incs 5 year growth outlookJuly 2025 Macro Moves & Community Consensus Trade Alerts - baoquankhu1.vn
Registration-Ready: How 2026’s Clinical Leaders Are Beating Cancer Benchmarks - The AI Journal
Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks - Baystreet.ca
Oncolytics Biotech Strengthens Leadership for Oncology Trials - Intellectia AI
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks - Newswire Canada
THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack - The Globe and Mail
Trade Recap: What analysts say about SFBS stockBreakout Watch & Weekly High Return Forecasts - baoquankhu1.vn
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Director Bernd Seizinger Acquires 100,000 Shares - MarketBeat
Stocks In Play - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Announces Results of Special Meeting of Shareholders - marketscreener.com
Oncolytics Biotech Shareholders Approve Redomiciliation to Nevada and New Incentive Plan - TipRanks
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders - The Manila Times
Oncolytics Biotech Inc. Announces Approval of Shareholder Resolutions at Special Meeting - Quiver Quantitative
ONCY: All resolutions, including corporate moves and the 2026 Incentive Plan, were approved by shareholders - TradingView
Oncolytics Biotech Inc Announces Key Executive Appointments - TradingView
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - The Globe and Mail
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics - Sahm
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Oncolytics Biotech Inc. Appoints John McAdory as Executive Vice President of Strategy and Operations - marketscreener.com
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era - The Manila Times
Oncolytics Biotech Bolsters Late-Stage Cancer Push With New Strategy and Biostatistics Leaders - TipRanks
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - The Globe and Mail
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points - GlobeNewswire
Oncolytics Biotech Inc. Appoints New Executive Team Members to Enhance Strategic Operations and Clinical Development - Quiver Quantitative
Where are the Opportunities in (ONC) (ONC:CA) - Stock Traders Daily
Stop Loss: How Oncolytics Biotech Inc stock reacts to Fed rate cutsEarnings Risk Report & Free Reliable Trade Execution Plans - Bộ Nội Vụ
Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology - Intellectia AI
Oncolytics Biotech (ONCY) leadership strengthens as Pelareorep advances - MSN
Oncolytics Biotech Data Signal Registration Path for Pelareorep Combo in Third-Line Anal Cancer - TipRanks
Pelareorep-atezolizumab shows promising results in anal cancer - Investing.com
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - The Malaysian Reserve
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Globe and Mail
Oncolytics (ONCY) Presents Promising Data for SCAC Treatment - GuruFocus
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer - The Manila Times
Oncolytics Biotech Reports Promising Clinical Data for Pelareorep-Atezolizumab Combination in Third-Line Metastatic Anal Cancer - Quiver Quantitative
1.27%
자본화:
|
볼륨(24시간):